The Guardian reports on an e-mail it says describes a strategy used by the Pharmaceutical Research and Manufacturers of America and the European Federation of Pharmaceutical Industries and Associations to mobilize "patient groups to express concern about the risk to public health by non-scientific re-use of data." EFPIA said it is "engaging with stakeholders to share concerns with harmful 're-use' of data." "We believe it is important to engage with all stakeholders in the clinical trial ecosystem, including the patients who volunteer to participate in clinical trials, about the issue," PhRMA Senior Vice President Matt Bennett.

Related Summaries